Introduction
Regulation of gene expression is controlled through the combinatorial action of multiple transcription factors, which function to activate or repress transcription via binding to cis-regulatory elements present in target genes. Identi®cation of functional target gene promoters that are regulated by speci®c transcription factors is critical for initiating studies to increase understanding of the molecular mechanisms that control transcription. Furthermore, identi®cation of target gene promoters for normal and oncogenic transcription factors provides insight into the regulation of genes that are involved in control of normal cell growth, and dierentiation, as well as provide information critical to understanding cancer development.
It has been over 15 years since Ets was originally identi®ed as one of the two genes (Ets and Myb) transduced by the avian leukemia virus, E26 (Watson et al., 1990) ; (Reviewed in this issue by Blair and Athanasiou). Since the cloning of the v-ets gene, over 30 Ets domain-containing genes have been identi®ed, either by sequence homology or as sites of viral integration and activation. Ets genes have been characterized in species ranging from sponges, nematodes and insects to humans. The Ets family proteins are transcription factors containing a winged helixturn-helix DNA binding domain. (Reviewed (Ghysdael and Boureux, 1997; Graves and Petersen, 1998; Watson, 2001) ). All Ets transcription factors bind to unique GGAA/T DNA sequences (EBS, Ets Binding Sites). Such EBS have been identi®ed in the promoter/ enhancer regions of viral and cellular genes, and thus control the expression of genes critical for the proper control of cellular proliferation, dierentiation, development, hematopoiesis, apoptosis, metastasis, tissue remodeling, angiogenesis and transformation. Our current literature survey allowed identi®cation of over 200 Ets target genes, and the number of genes shown to be regulated via EBS is constantly increasing. This number of Ets target genes is between those previously estimated for p53 (estimated between 200 ± 300 target genes, (Tokino et al., 1994) ) and for the hormone receptor family (50 ± 100 genes; (Evans, 1988) ). Further establishing the importance of Ets factors, a recent study demonstrated that EBS were among the eight most important DNA motifs in minimal responsive synthetic promoters generated using random oligonucleotides (Edelman et al., 2000) . In addition to their importance in normal cellular control, based upon predominance of target genes, Ets products have also been implicated in several malignant and genetic disorders. For example, the human Ets genes, FLI1, TEL and ERG, are located at the translocation breakpoints of several leukemias and solid tumors, forming chimeric proteins believed to be responsible for tumorigenesis (Dittmer and Nordheim, 1998) ; (Mavrothalassitis and Ghysdael, Truong and BenDavid, in this issue) . In addition, Ets factors have been found to be overexpressed (e.g., Ets2 in prostate and breast cancer (Sapi et al., 1998; Sementchenko et al., 1998) ) or lost (e.g. PSE in prostate cancer (Nozawa et al., 2000) ) during cancer development. Most of the target genes that mediate phenotypes associated with dysregulated expression remain to be de®ned.
The importance of the Ets family of transcription factors in various biological and pathological processes necessitates the identi®cation of downstream cellular target genes of speci®c Ets proteins. Although some overlap in the biological function of dierent Ets proteins may exist, the emergence of a family of closely related transcription factors suggests that individual Ets members may have evolved unique roles, manifested through the control of speci®c target genes. Several key areas are critical for understanding what de®nes a functionally important Ets target gene: First, the functional importance of the EBS must be demonstrated by mutagenesis. Second, the Ets factor or factors responsible for transcriptional control of speci®c target genes need to be identi®ed. While extensive publications have identi®ed functionally important Ets binding sites (EBS) and thus, Ets target genes (Table 1) , relatively few investigations have identi®ed de®nitive target genes for a speci®c Ets factor. Third, it is becoming increasingly evident that cellular context de®nes the direction and magnitude of response to Ets factors. Indeed, future eorts will lead to discovery of the co-factors that modulate transcriptional regulation by Ets factors. Collectively, we are beginning to de®ne the molecular mechanisms that determine which Ets family member will regulate a particular target gene and are developing appropriate approaches to determine which target genes are necessary for Ets-dependent phenotypes.
Ets target genes: the past
Initially, identi®cation of Ets targets was based upon the presence of the GGAA/T core sequences in the promoters/enhancers of various cellular or viral regulatory regions. Subsequently, synthetic oligonucleotides containing presumptive Ets binding sites (EBS) have been used in electrophoretic mobility shift assays (EMSAs) with proteins prepared as nuclear extracts or by in vitro transcription/translation of speci®c Ets factor cDNAs. Competition using excess oligonucleotide or with oligonucleotides containing mutations in the presumptive EBS are tests for speci®city. The Ets factor(s) responsible for speci®c DNA-protein complexes has been identi®ed by antibody inhibition/supershift analyses. Transient transfection with native promoter ± reporter genes or reporters containing the minimal promoter linked to the putative Ets binding sites are often used to demonstrate transcriptional activation or repression via Ets factors. The functional importance of speci®c sequences can be further analysed using deletions of various regions in the promoter sequence. The importance of particular candidate EBS can thus be demonstrated by mutagenesis. Table 1 provides a list of Ets target genes that have been identi®ed using these approaches. Collectively, functional Ets sites have been characterized in viral genes and cellular genes encoding transcription factors, transforming and tumor-associated products, proteinases, cell cycle and apoptosis regulators, signaling molecules, receptors and other cell surface molecules, ligands and tissue speci®c products.
Ets target genes: the present
The consensus binding sites for several Ets factors have been determined by enrichment of high anity oligonucleotides from pools of oligonucleotides with random sequences. Such analyses have demonstrated that Ets family members often dier in their exact binding site preference outside of the GGAA/T core, with factor-speci®c recognition spanning nine to 15 base pairs (Ghysdael and Boureux, 1997; Graves and Petersen, 1998) . However, in the last several years it has become apparent that Ets factors are able to bind to sites that do not conform to their in vitro derived high anity consensus sequences. For example, the Jchain transcription factor NF-JB was puri®ed by DNA anity chromatography using sequences derived from the J-chain promoter and was subsequently found to be identical to PU.1. Signi®cantly, the NF-JB site does not contain what had been previously felt to be an invariant GGA core sequence, but rather AAGAAA (Shin and Koshland, 1993) . PU.1 has subsequently been found to bind to other sequences lacking the GGA core, including Macrophage scavenger receptor (AGAGAAGT, (Moulton et al., 1994) ) and IL-1b (GCAGAAGT (Buras et al., 1995; Kominato et al., 1995) ). Target gene speci®city and anity of Ets factors to EBS is ultimately controlled by the precise sequence context/geometry of the EBS in relation to other cis-elements. The importance of neighboring elements for maximizing function via EBS is explained in part by the ability of Ets factors to form complexes and act synergistically with members of other transcription factor families. One example of co-dependence between Ets and other transcription factors is the synergistic binding and cooperative activation via Ets1, CREB and AML1 non-consensus binding sites in the human T-cell receptor beta chain promoter. Furthermore, it has been suggested that such low-anity sites mediate cooperative concentration-dependent promoter regulation, while high-anity sites may be associated with constitutive activation (Halle et al., 1997 (Shirasaki et al., 1999; Czuwara-Ladykowska et al., submitted; Trojanowska, in this issue) . Furthermore, Fli1 has been shown to act as a repressor of Rb (Tamir et al., 1999) . Unique promoter interactions with speci®c Ets factors have also been demonstrated in the case of Ets2 (or Ets1) and Erg on the collagenase (MMP1) and stromelysin (MMP3) promoters. Erg appears to act as an activator of the collagenase promoter, while it inhibited stimulation of stromelysin promoter by Ets2, whereas Ets2 stimulated both (Buttice et al., 1996) . Recruitment of CBP/p300 by Ets2 seems to play an important role in activation of the stromelysin promoter (Jayaraman et al., 1999) . Importantly, Erg was not able to cooperate with CBP/p300 in the context of this promoter, which may explain dierential eects of Ets2 and Erg on the activity of this promoter.
Successful identi®cation of target genes controlled by one (or more) Ets factors will require the use of 
RNA-based approaches
Eorts to identify Ets target genes have often been based upon analysis of expression following gain or loss of function. Gain of function experiments employ constitutive or inducible expression of a family member, followed by identi®cation of dierentially expressed genes. Tetracycline-inducible expression of p42-Ets1 leads to increased expression of Caspase 1, which may account in part for the Fas-and low seruminduced apoptosis in the Ets1 expressing cells (Li et al., 1999a) . Several approaches are available to identify gene expression dierences including subtraction hybridization, dierential display, representational dierence analysis (RDA) and more recently, serial analysis of gene expression (SAGE) and Expression Array Analysis. Candidate target genes identi®ed by this approach can subsequently be evaluated in the knockout mutant mice (loss of function). Enforced expression experiments may result in aberrant expression level and distribution, leading to identi®cation of invalid target genes. It is noteworthy that most of the presumptive Myc target genes identi®ed by gain of function studies were found not to have altered expression in the Myc knockout (Bush et al., 1998 ).
This apparent discrepancy may be a re¯ection of celltype speci®city, cell cycle dependence, growth conditions or other experimental conditions.
Use of knockout/transgenic mice as models for identification of Ets target genes
The candidate target gene approach is based upon the biology of an Ets gene. Such an approach may be coupled with phenotypes observed in knockout and transgenic mice. Loss of function PU.1 results in absence of monocyte/macrophage development and B cells with abnormal T-cell and granulocytic development. Consistent with the myeloid phenotype, Northern analyses demonstrated that homozygous ( 7/7 ) mutant PU.1 mice have greatly reduced levels of mRNAs for the receptors for M-CSF, G-CSF and GM-CSF. Each of these receptors had been previously proposed to be PU.1 responsive. However, a RDA study allowed for the identi®cation of additional myeloid genes ( (Iwama et al., 1998) and references within). Similarly, the megakaryocytic lineage defects observed with the recent Fli1 knockout mice (Hart et al., 2000; Spyropoulos et al., 2000) suggests that genes whose expression is necessary for this lineage may be Fli1 targets. RT ± PCR studies demonstrate that gpIX (Hart et al., 2000) and c-mpl (Kawada et al., manuscript submitted) are reduced in mRNAs prepared Gagnon et al., 1999) d: deletions, m: mutation, e: EMSA; t: transfection of promoter-reporter, meth: methylation interference, f: footprinting, ivf: in vivo footprinting, MS: multiple (42) EBS. This table provides a list of those target genes that have been con®rmed by functional assays (i.e. transfection of reporter constructs linked to putative promoters with mutated or deleted EBS). In a few cases where functional assessments were not available, targets that were validated with in vitro assays (i.e. EMSA or footprinting) are also included from homozygous mutant mice, consistent with earlier in vitro studies (Alexander and Dunn, 1995; Bastian et al., 1999; Deveaux et al., 1996) . Caution is warranted however, since loss of a particular lineage may aect the expression of indirect target genes as well. Furthermore, tissue-speci®c alterations in presumptive target genes can occur as demonstrated by the initial RNase protection analysis of Ets2(
) mice (Yamamoto et al., 1998).
The transgenic (gain of function) animals that have been generated for Fli1 , Ets2 (Sumarsono et al., 1996) , PU.1 (Moreau-Gachelin et al., 1996) and TEL-PDEFb (Ritchie et al., 1999) will potentially facilitate target gene identi®cation. However, the transgenic approach will not provide as unambiguous a result as creating mice lacking expression of a speci®c Ets factor. First, the transgenic will have normal expression of the endogenous Ets factor, in addition to transgene expression. Second, improper timing, tissue context and level of ectopic expression may seriously compromise the value of the results using a transgenic approach.
One caveat/limitation to RNA based studies is that both direct and indirect target genes are identi®ed. Expression of direct target genes is due to the interaction of Ets proteins with the regulatory elements present in the gene. In contrast, the regulation of indirect target genes may be controlled via proteins encoded by direct target genes. While kinetic arguments (time course of induction of a presumptive direct target gene relative to the expression of the Ets factor) can be used, an alternative approach to demonstrate direct regulation of a gene is the utilization of ER fusion constructs (Littlewood et al., 1995) . Fusion of the estrogen receptor hormone binding domain (ER-HBD) to other proteins has been shown to result in liganddependent inducible activity of the resultant chimeric protein. Thus, in the absence of the ligand, the chimeric protein is expressed, but sequestered in the cytoplasm. Functional activity of the protein is dependent upon hormone addition and subsequent nuclear localization. Simultaneous addition of cycloheximide and hormone allows activation of target genes in the absence of protein synthesis and thus provides a method to distinguish primary and secondary target genes. One limitation to this approach is that not every protein fused ER turns out to be regulatable by ligand. In addition, in some cases, fusion of the ER domain to the amino terminus of the protein works better than fusion at the carboxy terminus (Trevor Littlewood, personal communications) . Furthermore, such fusion protein may lose some of its ability to interact with its protein partners, which may also compromise experimental results. Although successful estrogen-mediated expression of ERM has been demonstrated (Pelczar et al., 1997) , this chimeric protein has not yet been used to identify or validate ERM target genes. Not all attempts to develop hormone-regulated functionality will be successful. For example, we recently found that the human Fli1-Estrogen receptor fusion construct, joining the ER ligand binding domain to either the carboxy or amino terminal end of Fli1, was not regulated by hormone. Whether this was due in part to the observed functional interference between Fli1 and steroid hormone receptors (Darby et al., 1997) (Espinas et al., 1994) . However, in vivo footprinting studies do not allow identi®cation of the speci®c Ets factor responsible for regulation of a given target. Other methodologies, such as whole-genome PCR and chromatin immunoprecipitation, have begun to be used for identi®cation of targets for speci®c Ets factors. These methods allow the cloning of genomic DNA, based upon the presence of binding sites for a particular transcription factor.
Whole genome polymerase chain reaction (WGPCR)
WGPCR is one method that identi®es direct target gene promoters/enhancer sequences for DNA binding proteins . Brie¯y, genomic DNA fragments are immuno-selected based upon their binding to a speci®c transcription factor and ampli®ed by the polymerase chain reaction. The utility of WGPCR for the identi®cation of Ets1 factor binding sites has been demonstrated. Among the clones isolated, three genomic fragments were found to be derived from the regulatory regions of the human serglycin, preproapolipoprotein C II and the Egr1 genes. Furthermore, the promoters of each of these genes contain consensus EBS able to bind to Ets proteins in EMSAs (Robinson et al., 1997) .
Chromatin immunoprecipitation (ChIPs)
Chromatin immunoprecipitation is an exciting approach for the identi®cation of target genes based upon in vivo occupancy of a promoter by a transcription factor and enrichment of transcription factor bound chromatin by immunoprecipitation using antibody against a speci®c transcription factor (Orlando, 2000) . With this approach, cells are incubated with formaldehyde to crosslink proteins to DNA, and sonicated chromatin is subsequently incubated with Ets speci®c antibody or`no antibody' control. Washed immunoprecipitates are analysed by PCR to determine whether candidate target genes are enriched in the Etsimmunoprecipitated samples. This approach has recently been used to demonstrate that the Rb gene is bound by Fli1 in vivo (Tamir et al., 1999) . Another recent study utilizing ChIPs has demonstrated that following LPS stimulation, multiple Ets factors (Elk1, Ets1/2) are bound to the TNFa promoter in vivo (Tsai et al., 2000) . It is important that ChIPs data be coupled with independent veri®cation of the functional im-portance of the binding sites identi®ed. Furthermore, DNA based approaches do not allow to immediately distinguish the direction of the interaction of a transcription factor (repression or activation) with the particular promoter.
Ets target genes: future directions
We will soon be able to generate libraries of Etsspeci®c target genes using in vivo chromatin immunoprecipitation. Subsequent DNA sequence analysis should begin to allow identi®cation of speci®c combinations of EBS proximal to binding sites for other transcription factors, allowing for better de®ni-tion of Ets target genes. Perhaps ChIP approaches using multiple antibodies, used sequentially, may allow identi®cation of in vivo synergistic interactions previously implicated by transient transfection assays or never before identi®ed. The role of post-translational modi®cations upon complex formation may be able to be evaluated in vivo using phosphorylation or acetylation speci®c antibodies, followed by Ets factor-speci®c antibodies.
Similarly, ChIPs provides a valuable approach to assess the in vivo kinetics of Ets factor binding to speci®c promoter sites and to assess whether single or multiple family members can bind a single promoter. It will be important to determine whether Ets factor occupancy on speci®c promoters is altered during dierentiation of speci®c lineages in normal development. We know that temporal speci®c expression of Ets factors occurs during development. Whether such changes can be correlated with dierences in occupancy of Ets target gene promoters and subsequent gene expression remains to be determined. For example, such studies may demonstrate whether TEL can compete directly with the transcriptional targets of Fli1, as well as indirectly block Fli1 transcriptional activity (Kwiatkowski et al., 1998) . Perhaps similar interplay between other Ets factors may also serve as a molecular switch between gene repression and activation and vice versa. The stable integration of speci®c promoter constructs provides a possible experimental system to simultaneously examine transcriptional activity and transcription factor occupancy (Boyd and Farnham, 1999) .
Co-localization studies
Confocal microscopy with double immunostaining is an approach to con®rm the co-localization of an Ets factor with its presumptive target gene within a particular set of cells within a speci®c tissue. From such analyses, we will determine if there are Etsdependent expression patterns for speci®c target genes that may be evident in a tissue or temporal speci®c manner. It is anticipated that in some tissues, expression of speci®c target genes would have an absolute requirement for a speci®c Ets factor and these genes would not be expressed in these tissues in the appropriate Ets homozygous knockout mice. On the other hand, in some tissues, the expression of Ets may not be absolutely required, suggesting that redundancy between Ets family transcription factors may be tissuespeci®c. Indeed, precise examination of the tissue and cellular expression of target genes in wild-type and homozygous mutant mice is likely to be the only way to identify tissue-speci®c redundant pathways. Initial analysis of target gene expression in the Ets2 knockout mouse clearly illustrates this complexity. Tissue-speci®c loss of expression was observed for several of the genes whose expression was altered; for example, Ets1, MMP3, MMP9 and uPA were found to be reduced in the skin, while the mRNAs for these genes were apparently unchanged in the mammary gland . It remains to be determined whether dierent cell types (e.g., basal cells versus epithelia cells versus stromal cells) in a particular tissue have identical Ets factor and/or target gene pro®les.
Trap approaches for the identification of target genes
Future studies may exploit an inducible gene trap approach similar to that recently used to identify homeoprotein-regulated loci (Mainguy et al., 2000) for identi®cation of Ets-responsive genes. Brie¯y, independent clones are isolated from a library of ES cells constructed to have randomly integrated reporters under the control of the individual`trapped' gene promoters (promoter trap). To identify an Ets responsive gene, single cell clones can be incubated with puri®ed fusion protein, consisting of the Ets domain of a speci®c Ets factor fused to the third helix of the homeodomain for ecient internalization into the ES cell. The internalized recombinant protein should compete with endogenous Ets proteins binding to EBS present in Ets-responsive genes expressed in ES cells. This approach should enrich for fusion transcripts corresponding to the Ets responsive genes. In addition, since each clone in the library is in ES cells, this method could also allow for rapid generation of knockout mice for speci®c Ets-target genes.
Modifiers of Ets function
Genetic screens for modi®ers of Ets function will further enhance our understanding of the mechanisms that control the expression of Ets target genes. Such studies could be initiated using one of the eight Drosophila Ets genes (see article in this issue, Hsu and Schulz). Both gain of function and loss of function phenotypes provide foundations for screening for modi®ers of phenotype (Rebay et al., 2000) . Availability of the complete sequence of the Drosophila genome and the use of Drosophila genetics (Rubin and will provide an approach to identify modi®ers of Ets function (as well as a means to identify targets). Once identi®ed, these genes may serve as probes for the identi®cation of relevant mammalian target genes and modulators of Ets transcription factors (Ashburner et al., 2000) .
